Caliway Biopharmaceuticals Co. L
6919
Pozycja w akcjach
#4342
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Cena akcji
$2.29
Kapitalizacja rynkowa
$3.56B
Zmiana (1 dzień)
-2.50%
Zmiana (1 rok)
-57.22%
Kraj
TW
Handel Caliway Biopharmaceuticals Co. L (6919)
Kategoria
Healthcare
Historia stopy dywidendy dla Caliway Biopharmaceuticals Co. L (6919)
Stopa dywidendy (TTM) dla Caliway Biopharmaceuticals Co. L (symbol akcji: 6919) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Caliway Biopharmaceuticals Co. L (6919) od 2025 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
| Rok | Stopa dywidendy | Zmień |
|---|---|---|
| 2025 | 0.00% | 0.00% |
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji
| Firma | Stopa dywidendy | Kraj |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
NL
|
|
| 0.00% |
CH
|
